Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis

Cancer Medicine

Volumn 4, Issue 2, 2015, Pages 253-267

  Meier, Julia C ^a,b   Haendler, Bernard ^a   Seidel, Henrik ^a   Groth, Philip ^a   Adams, Robert ^a,c   Ziegelbauer, Karl ^a   Kreft, Bertolt ^a   Beckmann, Georg ^a   Sommer, Anette ^a   Kopitz, Charlotte ^a  

^a BAYER PHARMA AG   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

AKT; GDF15; Linear model analysis; Ovarian cancer; Platinum resistance

Indexed keywords

CARBOPLATIN; CHECKPOINT KINASE 2; GROWTH DIFFERENTIATION FACTOR 15; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P27; ANTINEOPLASTIC AGENT; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GDF15 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CELL MOTION; DNA MICROARRAY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE SILENCING; GENETICS; OVARIAN NEOPLASMS; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MICE; MICE, SCID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964694424     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.354     Document Type: Article

References (50)

1. Siegel, R., D. Naishadham, and A. Jemal . 2013. Cancer statistics, 2013. CA Cancer J. Clin. 63:11-30.
2. Lowe, K. A.. et al., 2013. An international assessment of ovarian cancer incidence and mortality. Gynecol. Oncol., 130:107-114.
3. Bray, F., et al. 2005. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int. J. Cancer 113:977-990.
4. Bray, F., et al., 2005. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. 113:977-990.
5. Yurkovetsky, Z., et al. 2010. Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol. 28:2159-2166.
6. Das, P. M., and R. C., Jr. Bast . 2008. Early detection of ovarian cancer. Biomark. Med. 2:291-303.
7. Siddik, Z. H. 2003. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279.
8. Wang, D., and S. J. Lippard . 2005. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4:307-320.
9. Galluzzi, L., et al. 2012. Molecular mechanisms of cisplatin resistance. Oncogene 31:1869-1883.
10. Stewart, D. J. 2007. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 63:12-31.
11. Bock, A. J., et al. 2010. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. Int. J. Gynecol. Cancer 20:1448-1455.
12. Staff, A. C., et al. 2010. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol. Oncol. 118:237-243.
13. Khaled, Y. S., E. Elkord, and B. J. Ammori . 2012. Macrophage inhibitory cytokine-1: a review of its pleiotropic actions in cancer. Cancer Biomark. 11:183-190.
14. Kempf, T., and K. C. Wollert . 2009. Growth-differentiation factor-15 in heart failure. Heart Fail. Clin. 5:537-547.
15. Koopmann, J., et al. 2004. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin. Cancer Res. 10:2386-2392.
16. Fairlie, W. D., et al. 1999. MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J. Leukoc. Biol. 65:2-5.
17. Zimmers, T. A., et al. 2005. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 23:543-548.
18. Yang, H., et al. 2003. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol. Cancer Ther. 2:1023-1029.
19. Rebbeck, T. R. 2000. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 18(Suppl. 21):100s-103s.
20. Wang, X., S. J. Baek, and T. E. Eling . 2013. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem. Pharmacol. 85:597-606.
21. Mimeault, M., and S. K. Batra . 2010. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J. Cell. Physiol. 224:626-635.
22. Kim, K. K., et al. 2008. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 29:704-712.
23. Corre, J., et al. 2012. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res. 72:1395-1406.
24. Behrens, B. C., et al. 1987. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47:414-418.
25. Galavotti, S., et al. 2013. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene 32:699-712.
26. Cramer, D. W., W. R., Welch . 1983. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J. Natl Cancer Inst. 71:717-721.
27. Dai, Y., et al. 2005. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J. Biol. Chem. 280:40066-40073.
28. Bret, C., et al. 2011. SULFs in human neoplasia: implication as progression and prognosis factors. J. Transl. Med. 9:72.
29. Campbell, R. A., et al. 2001. Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α: a new model for anti-estrogen resistance. J. Biol. Chem. 276:9817-9824.
30. Meier, C. R., S. Schmitz, and H. Jick . 2002. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22:303-309.
31. Zhao, L., et al. 2009. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res. 69:7696-7703.
32. Cramer, D. W., G. B. Hutchison, W. R. Welch, R. E. Scully, and K. J. Ryan . 1983. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J. Natl Cancer Inst.. 71:711-716.
33. Kelly, J. A., M. S. Lucia, J. R. Lambert . 2009. p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms. Cancer Lett. 277:38-47.
34. Negri, E., et al. 1991. Pooled analysis of 3 european case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int. J. Cancer 49:50-56.
35. Wang, L., et al. 2012. Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer. Mol. Cancer Ther. 11:2401-2409.
36. Abbas, T., and A. Dutta . 2009. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9:400-414.
37. Singh, M., et al. 2013. Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance. BMC Cancer 13:233.
38. Bartholomeusz, C., and A. M. Gonzalez-Angulo . 2012. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin. Ther. Targets 16:121-130.
39. Abedini, M. R., et al. 2010. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 29:11-25.
40. Liu, T., et al. 2003. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res. 63:5034-5040.
41. Lee, D. H., et al. 2003. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res. 63:4648-4655.
42. Baek, S. J., et al. 2006. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 131:1553-1560.
43. Martinez, J. M., et al. 2006. Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth. J. Pharmacol. Exp. Ther. 318:899-906.
44. Chu, I. M., L. Hengst, and J. M. Slingerland . 2008. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 8:253-267.
45. Garcia-Fernandez, R. A., et al. 2011. Combined loss of p21waf1/cip1 and p27kip1 enhances tumorigenesis in mice. Lab. Invest. 91:1634-1642.
46. Liu, Y., et al. 2009. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4:37-48.
47. Rayess, H., M. B. Wang, and E. S. Srivatsan . 2012. Cellular senescence and tumor suppressor gene p16. Int. J. Cancer 130:1715-1725.
48. Surowiak, P., et al. 2008. Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor. Histol. Histopathol. 23:531-538.
49. Bonome, T., et al. 2005. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 65:10602-10612.
50. Yap, T. A., C. P. Carden, and S. B. Kaye . 2009. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 9:167-181.